エピソード

  • Hope in a Dose | Ep 1 | Breaking Ground: What Makes CGT Phase Trials Different

    Hope in a Dose | Ep 1 | Breaking Ground: What Makes CGT Phase Trials Different
    2026/04/06
    Discover what sets cell and gene therapy (CGT) clinical trials apart. From “one-and-done” treatments to complex logistics and evolving regulations, our first episode of this podcast series explores the unique challenges and transformative potential of CGT studies. Join us as we dive into science, strategy, and stories behind Hope in a Dose.
    続きを読む 一部表示
    8 分
  • Hope in a Dose | Ep 7 | Long-term Follow Up in Cell and Gene Therapy Trials

    Hope in a Dose | Ep 7 | Long-term Follow Up in Cell and Gene Therapy Trials
    2026/04/06
    In this episode we tackle one of the most critical aspects of these programs: long-term follow-up. Why is it so important? With CAR-T therapies, lentiviral vector-based treatments, and gene editing approaches requiring up to 15 years of follow-up, we’re looking at a rapidly growing population of patients who will need monitoring for years—sometimes decades. Featuring insights from Gordon Cummings, Global Growth Lead, this episode highlights why long-term follow-up is essential, how sponsors can reduce burden on patients and sites, and the exciting role of data technologies in making these studies more efficient.
    続きを読む 一部表示
    18 分